Market Trends Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3GBy admin8996erT0allMarch 21, 2025 TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS) Thursday said that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration…
